Bitcoin price today: rises to $116.5k on Trump 401k order, altcoins rally
Investing.com -- Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings per share reaching $12.89 compared to the $8.43 consensus estimate. Revenue also beat forecasts, coming in at $3.68 billion versus the expected $3.28 billion.
The biopharmaceutical company’s total revenue increased 4% YoY, driven by strong performance across several key products. Dupixent global net sales, recorded by Sanofi (NASDAQ:SNY), grew 22% to $4.34 billion, while EYLEA HD U.S. net sales jumped 29% to $393 million. However, combined EYLEA HD and EYLEA U.S. net sales decreased 25% to $1.15 billion.
The stock is up 0.3% following the results.
"Regeneron (NASDAQ:REGN) had a strong quarter, marked by significant growth in U.S. sales of EYLEA HD and global sales of Dupixent and Libtayo along with multiple regulatory approvals," said Leonard Schleifer, Chief Executive Officer of Regeneron.
The company reported several regulatory achievements during the quarter, including FDA approval for Lynozyfic for relapsed or refractory multiple myeloma and Dupixent approvals for bullous pemphigoid and chronic spontaneous urticaria. The FDA also accepted for priority review Libtayo’s application for adjuvant cutaneous squamous cell carcinoma.
Regeneron updated its financial guidance for 2025, adjusting its R&D and SG&A expense projections. The company now expects non-GAAP R&D expenses of $5.1-$5.2 billion and non-GAAP SG&A expenses of $2.45-$2.55 billion.
During the quarter, Regeneron returned over $2.3 billion to shareholders through share repurchases and dividends. The company’s board declared a cash dividend of $0.88 per share, payable on September 3, 2025.